HGH Fragment 176-191 is the naturally occurring C-terminal portion of human growth hormone that contains the fat-metabolic signaling region. It represents the minimal active sequence for GH-mediated lipolysis without the growth-promoting or diabetogenic effects of the full hormone.
Research Applications
Fat metabolism, lipolysis signaling, body composition research without IGF-1 elevation, and comparative studies with AOD-9604.
Dosage Information (Research Use)
Research protocols: 250-500 mcg subcutaneously, 1-2 times daily, typically on an empty stomach. Research use only.
Reconstitution & Handling
Standard BAC water reconstitution.
Half-Life & Pharmacokinetics
Short — approximately 30 minutes. Multiple daily doses used in research protocols.
Reported Observations in Literature
Generally well-tolerated. Injection site irritation reported. No significant effects on glucose or IGF-1.
Key Research References
- Wu Z, et al. “The C-terminal fragment 177-191 of growth hormone has lipolytic effects.” Biochem Biophys Res Commun. 1993